Publication List
Müller, R.H., Mehnert, W. Particle and Surface Characterisation, medpharm Scientific Publishers, Stuttgart (1997).
Wätzig, H., Mehnert, W., Bühler, W. Mathematik und Statistik kompakt, Wissenschaftliche Verlagsgesellschaft (2009).
Book Chapters
Mehnert W.
Phytopharmaka–Vergleichende Qualitätsbeurteilung, in: Pharmazeutische Technologie:Moderne Arzneiformen. R.H. Müller, G.
Hildebrand, (eds) 2.Auflage,Wissenschaft-
liche
Verlagsgesellschaft, Stuttgart, 109-118 (1998).
Mehnert,
W., Therapeutische Äquivalenz, in: Lehrbuch
der Klinischen Pharmazie. Jaehde, U., Radziwill, R., Mühlebach, S.,
Schunack, W. (eds.), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 39-53
(1998).
Mehnert, W., Bioverfügbarkeit,
Bioäquivalenz, in: Grundlagen der
Arzneiformenlehre, Galenik 2. Herzfeldt, C.-D., Kreuter, J., (eds),
Springer-Verlag Berlin, 510-535 (1999).
Böhning, D., Malzahn, U., Schlattmann, P., Dammann,
U.-P., Mehnert, W., Holling, H., Schulze, R. The Application of Statistical
Methods of Meta-Analysis for Heterogeneity Modelling in Medicine, Pharmacy,
Psychology, Quality Control and Assurance, in: Mathematics – Key Technology
for the Future. Jäger, W., Krebs, H.-J. (eds),
Springer-Verlag Heidelberg, 533-553 (2003).
Mehnert,
W., Therapeutische Äquivalenz, in: Lehrbuch
der Klinischen Pharmazie. Jaehde, U., Radziwill, R., Mühlebach, S.,
Schunack, W. (eds.), Wissenschaftliche Verlagsgesellschaft, Stuttgart, 49-66
(2003), 2. Auflage.
Schäfer-Korting M., Mehnert W.: Delivery of lipophilic
compounds with lipid nanoparticles – application in dermatics and for
transdermal therapy. In: Nastruzzi C (ed) Liposheres in Drug Targets and
Delivery: Approaches, Methods, and Applications,CRC Press,
Mäder K.,
Mehnert W.: Solid lipid nanoparticles – concepts, procedures and
physicochemical aspects. In: Nastruzzi C (ed) Liposheres in Drug Targets and
Delivery: Approaches, Methods, and Applications. CRC Press,
Müller, R. H., Mehnert, W., Souto, E.B.: Solid lipid
nanoparticles (SLN) and nanostructured lipid carriers (NLC) for dermal
delivery. In: Bronaugh (eds) Percutaneous Absorption. Marcel Dekker, Inc.,
Review Articles
K.-H.
Frömming, W. Mehnert. Arzneimittelwirkung und Nahrungsaufnahme. Der
informierte Arzt 2, 4 (1981).
W.
Mehnert, D. Ohlendorf. Bioverfügbarkeit – Bioäquivalenz.Eine Check-Liste.
Krankenhauspharmazie
8, 55 (1987).
R.
H. Müller, W. Mehnert. Neue Arzneimittel mit Nanopartikeln. Dtsch. Apoth.
Ztg. 135, 2597 (1995).
M. Eder, W.
Mehnert. Bedeutung pflanzlicher Begleitstoffe in Extrakten. Pharmazie 53, 285-293 (1998).
Eder, M., Mehnert, W.: Pflanzliche Begleitstoffe – wertvolle Hilfsstoffe oder überflüssiger Ballast? Pharmazie in unserer Zeit, 29/6, 377-384 (2000).
Mehnert, W.,
and K. Mäder. Solid
lipid nanoparticles. Production, characterization and applications. Adv Drug Deliv Rev
47(2-3):165-96 (2001).
W.
Mehnert. Lipid-Nanodispersionen – kolloidales Trägersystem zur dermalen
Applikation. SwissPharma 24: 13-16(2002).
Danker, K., Dathe, M., Kleuser, B.,
Kramer, K., Liesenfeld, O., Mehnert, W., Niehus, H., Reutter, W. und M.
Schäfer-Korting. Innovative Wirkstoffe und Carriersysteme für eine gezielte
Arzneimitteltherapie. BIOspektrum 9: 315-317 (2003).
Mehnert, W. Thermoanalytische Verfahren
und ihre Anwendung in der Praxis. PZ Prisma 11: 223-232 (2004).
Schäfer-Korting,
M., Mehnert, W., Korting, H.-C.: Lipid nanoparticles for improved topical
application of drugs for skin diseases. Advanced
Drug Delivery Reviews 59:
427-443 (2007).
Research Articles
G.
Vetter, W. Mehnert, K.-H. Frömming. In vitro-/In vivo-Korrelation nach Einnahme
mikroverkapselter Acetylsalicylsäure mit einem Fruchtsaftgetränk. Acta
Pharm. Technol. 27, 109 (1981).
K.-H.
Frömming, W. Mehnert, G. Vetter. Beeinflussung der relativen Bioverfügbarkeit
von Riboflavin durch eine Einnahmeflüssigkeit. Arzneim.-Forsch. 31, 2159 (1981).
K.-H.
Frömming, W. Mehnert, G. Vetter. Über den Einfluß eines Fruchtsaftgetränkes auf
die Magenentleerungsgeschwindigkeit und die Bioverfügbarkeit von
Acetylsalicylsäure. Dtsch. Apoth. Ztg. 121, 373 (1981).
W.
Mehnert, G. Vetter, K.-H. Frömming. Über den Einfluß eines Fruchtsaftgetränkes
auf die in vitro-Wirkstoff-Freisetzung aus mikroverkapselter Acetylsalicylsäure.
Dtsch. Apoth. Ztg. 121, 501
(1981).
K.-H.
Frömming, V. Wedelich, W. Mehnert. Influence of Cyclodextrins on Nitrosation of Drugs.
J. Inclus. Phenom. 2,
605 (1984).
K.-H.
Frömming, V. Wedelich, W. Mehnert, A. Lange, R. Hosemann. Einschlußverbindungen
von Cyclodextrinen mit Piperazin. Arch. Pharm. 320, 294
(1987).
V. Wedelich, W. Mehnert, K.-H. Frömming. In Vitro
Nitrosation of Ephedrine in the Presence of Cyclodextrins. J. Inclus.
Phenom. 5, 621 (1987).
K.-H. Frömming, V. Wedelich, W. Mehnert. Nitrosation
of Mefenorex in the Presence of Cyclodextrins. J. Inclus. Phenom. 5,
625 (1987).
J.
Szulecki, A. Kubis, W. Mehnert, K.-H. Frömming. Untersuchungen über mit
Methylcellulosen behandelte Brandwundverbände. Pharm. Ztg. Wiss. 1, 56
(1988).
K.-H. Frömming, T. Gelder, W. Mehnert. Inclusion
Compound of ß-Cyclodextrin and Vitamin A Acetate. Acta Pharm. Technol. 34,
152 (1988).
K.-H.
Frömming, N. Eisenbach, W. Mehnert.Beeinflussung biopharmazeutischer
Eigenschaften von Arzneistoffen durch pflanzliche Begleitstoffe am Beispiel von
Khellin in einem Ammi visnaga-Trockenextrakt.
K.-H. Frömming, C. Kraus, W. Mehnert. Physico-Chemical
Properties of the Mixed Micellar Solutions of Solutol HS 15 and Sodium
Deoxycholate. Acta Pharm. Technol. 36,
214 (1990)
C.
Kraus, W. Mehnert, K.-H. Frömming. Hemolytic Activity of Mixed Micellar Solutions of
Solutol HS 15 and Sodium Deoxycholate. Acta Pharm. Technol.
36, 221 (1990).
C. Kraus, W. Mehnert, K.-H. Frömming. Interactions of
ß-Cyclodextrin with Solutol HS 15 and their Influence on Diazepam
Solubilization. Pharm. Ztg. Wiss. 4,
11 (1991).
K.-H. Frömming, R. Fridrich, W. Mehnert. Inclusion
Compounds of Cholesterol and ß-Cyclodextrin. Eur. J. Pharm. Biopharm. 39, 148
(1993).
R. Schuhmann, W. Mehnert, R.H. Müller. Stability of
O/W Emulsion I: Coulter Counter based Coalescence Assay to determine the
Stability of Emulsions against Addition of Electrolyte. Pharm. Industrie
55, 701 (1993).
C. Schwarz, W. Mehnert, J.-S. Lucks, R.H. Müller. Solid
Lipid Nanoparticles (SLN) for Controlled Drug Delivery. I: Production,
Characterization and Sterilisation. Journal of Controlled Release 30, 83 (1994).
V.
Bothmann, W.G. Schmidt, W. Mehnert, K.-H. Frömming. Herstellung von Pellets in
einem Labor-Rotorgranulator. Pharm. Industrie 56, 570 (1994).
A. Preiss, W. Mehnert, K.-H. Frömming. Complexation of
Hydrocortison with ß-Cyclodextrin and Hydroxy-propyl-ß-Cyclodextrin. Arch.
Pharm. 327, 729 (1994).
A. Preiss, W. Mehnert, K.-H. Frömming. In vitro
hydrocortisone release from ointments in presence of cyclodextrins. Pharmazie
49,
902 (1994).
R.
H. Müller, W. Mehnert, J.-S. Lucks, C. Schwarz, A. zur Mühlen, H. Weyhers, C.
Freitas, D. Rühl. Solid
Lipid Nanoparticles (SLN) - An Alternative Colloidal Carrier System for
Controlled Drug Delivery. Eur. J. Pharm. Biopharm.
41, 62 (1995).
A. Preiss, W. Mehnert, K.-H. Frömming. The Inclusion
Compound of Emulsified Cetostearyl Alcohol with ß- Cyclodextrin and a Competitive Reaction with a
Hydrocortisone/ß- Cyclodextrin Inclusion Compound in an Oil-in-Water Cream. Journal
of Inclusion Phenomena and Molecular Recognition in Chemistry 18,
331 (1994).
A.
Preiss, W. Mehnert, K.-H. Frömming. Penetration of hydrocortisone into excised human skin
under theinfluence of cyclodextrins. Pharmazie 50, 121 (1995).
W. G. Schmidt, W. Mehnert, K.-H. Frömming. Controlled
Release of Theophylline from Spherical Matrices Preparedin a Laboratory Scale
Rotor-Granulator - Variation of Release Rate and Initial
Release. Eur. J.
Pharm. Biopharm. 41, 132 (1995).
H. Haubitz, W. Mehnert, K.-H. Frömming Preparation of
Theophylline Multiple Units Tablets.
Pharm.
H. Weyhers, W. Mehnert, R. H. Müller. Analysis of
Particle Size Distribution of Micronized Lactose by Laser Diffractometry.
M. Bergmann, W. Mehnert, K.-H. Frömming. Dependence of
Quality of Freeze-Dried Diazepam-Mannitol on Some Processing Conditions. Eur. J. Pharm. Biopharm. 42, 171
(1996).
A. zur Mühlen, E. zur Mühlen, H. Niehus, and W. Mehnert.
Atomic Force Microscopy Studies of Solid Lipid Nanoparticles. Pharm. Res.
13, 1411 (1996).
W. G. Schmidt, W. Mehnert, K.-H. Frömming. Controlled
Release from Spherical Matrices Prepared in a Laboratory Scale Rotor-Granulator
- Release Mechanism Interpretation Using Individual Pellet Data. Eur. J.
Pharm. Biopharm. 42, 348 (1996).
R.H. Müller, S. Maaßen, H. Weyhers, W. Mehnert.
Phagozytic Uptake and Cytotoxicity of Solid Lipid Nanoparticles (SLN)
Sterically Stabilized with Poloxamine 908 and Poloxamer 407. Journal of Drug
Targeting 4, 161 (1996).
R.H.
Müller, D. Rühl, S. Runge, K. Schulze-Forster, W. Mehnert. Cytotoxicity of Solid Lipid Nanoparticles as a
Function of the Lipid Matrix and the
Surfactant. Pharm. Res. 14,
458 (1997).
R.H. Müller, S. Maassen, C. Schwarz, W. Mehnert. Solid
lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. Journal
of Controlled Release 47, 261
(1997).
R.
H. Müller, H. Weyhers, A. zur Mühlen, A. Dingler, W. Mehnert. Solid Lipid
Nanoparticles - ein neuartiger Wirkstoff-Carrier für Kosmetika und
Pharmazeutika, 1. Mitteilung: Systemeigenschaften, Herstellung und Scaling up. Pharm. Ind. 59, 423 (1997).
W.
Mehnert, A. zur Mühlen, A. Dingler, H. Weyhers, R.H. Müller. Solid Lipid
Nanoparticles - ein neuartiger Wirkstoff-Carrier für Kosmetika und
Pharmazeutika, 2. Mitt.: Wirkstoff-Inkorporation, Freisetzung und
Sterilisierbarkeit. Pharm. Ind. 59,
511 (1997).
R.H.
Müller, A. Dingler, H. Weyhers, A. zur Mühlen, W. Mehnert. Solid Lipid
Nanoparticles - ein neuartiger Wirkstoff-Carrier für Kosmetika und
Pharmazeutika, 3. Mitteilung: Langzeitstabilität, Gefrier- und Sprühtrocknung,
Toxizität, Anwendung in Kosmetika und Pharmazeutika.
C. Schwarz, W. Mehnert. Freeze-drying of drug-free and
drug-loaded solid lipid nanoparticles (SLN). Int. J. Pharm. 157, 171 (1997).
H.
Weyhers, W. Mehnert, R. H. Müller. Analysis of Particle Size Distribution of Micronized
Lactose by Laser Diffractometry. Drugs made in Germany 40, 66 (1997).
E.
Berkel, W. Mehnert, K.-H. Frömming. Enzymatic Hydrolysis of Chloramphenicol Palmitate in
Presence of ß-Cyclodextrin. Pharmazie 53, 323-326 (1998).
A. zur Mühlen, C. Schwarz, W. Mehnert. Solid Lipid
Nanoparticles (SLN) for controlled drug delivery- drug release and release
mechanism. Eur. J.
Pharm. Biopharm.
45, 149-155 (1998).
C. Schwarz, W. Mehnert. Solid lipid Nanoparticles
(SLN) for controlled drug delivery
II. Drug incorporation and physicochemical
characterization. J Microencapsul 16: 205-13 (1999).
Eder, M., Mehnert, W.: Lösungsverhalten von Digoxin in Gegenwart pflanzlicher Begleitstoffe aus Digitalis-lanata-Trockenextrakten, Teil 1: Löslichkeit und Lösungsgeschwindigkeit. Pharmazie 55:928-933 (2000).
Maia,
C.S., Mehnert, W., M. Schäfer-Korting. Solid lipid nanoparticles as drug carriers for topical
glucocorticoids. Int J Pharm 196: 165-167 (2000).
Santos Maia,
C., Mehnert, W., Schaller, M., Korting, H.C., Gysler, A., Haberland, A.,
and M. Schäfer-Korting. Drug Targeting by Solid Lipid Nanoparticles for Dermal
Use. J Drug Targeting 10: 489-495 (2002).
Haberland, A.,
Santos Maia, C., Jores, K., Dürrfeld, M., Mehnert, W., Schimke, I., Christ, B.
and M. Schäfer-Korting. Albumin Effects on Drug Absorption and Metabolism in Reconstructed
Epidermis and Excised Pig Skin. Altex 20: 3-9 (2003).
Jores, K.,
Mehnert, W. and K. Mäder. Physicochemical Investigations on Solid Lipid Nanoparticles and on
Oil-Loaded Solid Lipid Nanoparticles: A Nuclear Magnetic Resonance and Electron
Spin Resonance Study. Pharm Res 20: 1274-1283 (2003).
Jores, K.,
Mehnert, W., Drechsler, M., Bunjes, H., Johann, C. and K. Mäder. Investigations on the structure of solid lipid
nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon
correlation spectroscopy, field-flow fractionation and transmission electron
microscopy. J Control Release 95: 217-227 (2004).
Sivaramakrishnan R,
Nakamura C, Mehnert W, Korting, HC, Kramer KD, Schäfer-Korting M:
Glucocorticoid entrapment into lipid carriers – characterization by parelectric
spectroscopy and influence on dermal uptake. J Contr Release 97: 493-502 (2004).
Münster, U., Nakamura, C., Haberland, A., Jores, K., Mehnert, W.,
Rummel, S., Schaller, M., Zouboulis, Ch., Blume-Peytavi, U. and M.
Schäfer-Korting. RU 58841-myristate – a prodrug for topical
treatment of acne and androgenetic alopecia. Pharmazie 60: 8-12 (2005).
Jores, K., Haberland, A., Wartewig, S., Mäder, K. and W. Mehnert. Solid Lipid Nanoparticles
(SLN) and Oil-Loaded SLN Studied by Spectrofluorometry and Raman Spectroscopy. Pharm Res 22: 1887-1897 (2005).
Lombardi Borgia, S.,
Regehly, M., Sivaramakrishnan, R. Mehnert, W., Korting, H.C., Danker, K.,
Röder, B., Kramer, K.D. and M. Schäfer-Korting. Lipid nanoparticles for skin
penetration enhancement – correlation to drug localization within the particle
matrix as determined by fluorescence and parelectric spectroscopy. J Contr Release 110: 151-163 (2005).
Müller, R.H.,
Runge, S., Ravelli, V., Mehnert, W., Thünemann, A:F. and E.B. Suoto. Oral bioavailability of cyclosporine: Solid lipid
nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 317:
82-89 (2006).
Souto, E.B.,
Mehnert, W. and R.H. Müller. Polymorphic behaviour of Compritol®888 ATO as bulk lipid and
as SLN and NLC. J Microencapsul 23: 417-433 (2006).
Weyhers, H., Löbenberg, R.,
Mehnert, W., Suouto, E.B. Kreuter, J. and R.H. Müller: In vivo Distribution of 125I-radiolabelled
Solid Lipid Nanoparticles.
Štecova, J., Mehnert, W., Blaschke, T., Kleuser, B., Sivaramakrishnan,
R., Zouboulis, C.C., Seltmann, H., Korting, H.C., Kramer, K.D., and M.
Schäfer-Korting. Cyproterone acetate loading to lipid nanoparticles for topical
acne treatment: particle characterisation and skin uptake. Pharm Res 24:
991-1000 (2007).
Braem,
C., Blaschke, T., Panek-Minkin, G., Herrmann, W., Schlupp, P., Paepenmüller,
T., Müller-Goymann, C., Mehnert, W., Bittl, R., Schäfer-Korting, M. and K.D.
Kramer. Interaction
of drug molecules with carrier systems as studied by parelectric spectroscopy
and electron spin resonance. J
Contr Release 119: 128-135 (2007).
Lombardi
Borgia, S., Schlupp, P., Mehnert, W., and M. Schäfer-Korting. In vitro Skin Absorption and Drug Release – a
Comparison of Six Commercial Prednicarbate Preparations for Topical Use. Eur J Pharm Biopharm 68: 380-389 (2008).
Schäfer-Korting, M., Mahmoud, A., Lombardi Borgia, S.,
Brüggener, B., Kleuser, B., Schreiber, S., Mehnert, W. Reconstructed Epidermis
and Full-Thickness Skin for Absorption Testing: Influence of the Vehicles used
on Steroid Permeation. ATLA 36: 1-12 (2008).
Proceedings
K.-H. Frömming, J. Norwig, W. Mehnert. Menadione
Inclusion Compounds with Mixtures of Natural Cyclodextrins. Proceedings of
the Fourth International Symposium on Cyclodextrins (eds. O. Huber, J.
Szejtli) in: Advances in Inclusion Science, Kluwer Academic Publishers,
M. Thoss, J. Norwig, W. Mehnert, K.-H. Frömming.
Improvement on Photostability of Several Essential Oils and Menadione by
Natural Cyclodextrins. s. cit. 1, p. 355.
J.
Norwig, T. Gelder, Ch. Kraus, W. Mehnert, K. Rehse, K.-H. Frömming. Some Interesting Aspects in 1H-NMR
Spectroscopy by Cyclodextrin Complexation. s. cit. 1, p. 205.
K.-H.
Frömming, W. Mehnert, P. Bady, C. Kraus, M. Stein, V. Wedelich. Competitive Reactions of Cyclodextrin Inclusion
Compounds. Minutes 5th International Symposium on Cyclodextrins (ed. D. Duchêne) Editions de Santé,
R.
Fridrich, W. Mehnert, K.-H. Frömming. Studies of the Inclusion Compound between
ß-Cyclodextrin and Cholesterol. s. cit. 4, p. 299.
E.M.
Berkel, W. Mehnert, K.-H. Frömming. Preparation and Characterization of a Chloramphenicol
Palmitate/ß-Cyclodextrin Inclusion Compound. Minutes 6th International
Symposium on Cyclodextrins (ed. D. Duchêne) Editions de Santé,
J.E.
Diederichs, W. Mehnert, J.S. Lucks, R.H. Müller. Microviscosity measurements for the optimization
ofliposome and emulsion formulations. Proceed. 6th Int. Conf. on Pharm. Technol. (APGI),
J.E. Diederichs, W. Mehnert, R.H. Müller. Differential
Scanning Calorimetry of parenteral fat emulsions. Proceed. 6th Int. Conf. on
Pharm. Technol. (APGI),
R.H. Müller, C. Schwarz, W. Mehnert, J.S. Lucks.
Production of Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery. Proceed.
Intern. Symp. Control. Rel. Bioct. Mater. 20, 480 (1993).
S. Maaßen, C. Schwarz, W. Mehnert, J.S. Lucks, F.
Yunis-Specht,B.W. Müller, R.H. Müller. Comparison of Cytotoxicity between
Polyester Nanoparticles and Solid Lipid Nanoparticles (SLN).
Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 20, 490
(1993).
R. H. Müller, C. Schwarz, A. zur Mühlen, W. Mehnert.
Incorporation of lipophilic Drugs and Drug Release Profiles of Solid Lipid Nanoparticles (SLN). Proceed.
Intern. Symp. Control. Rel. Bioact. Mater. 21, 146
(1994).
C. Schwarz, W. Mehnert. Sterilization of Drug-free and
Tetracaine-loaded Solid Lipid Nanoparticles (SLN). Proc. 1st World Meeting
APGI/APV,
C. Schwarz, C. Freitas, W. Mehnert, R. H.
Müller.Sterilization and Physical Stability of Drug-free and Etomidate-loaded
Solid Lipid Nanoparticles. Proceed. Intern.
Symp. Control. Rel. Bioact. Mater. 22, 766
(1995).
A. zur Mühlen, W. Mehnert. Drug Incorporation and
Delivery of Prednisolone Loaded Solid Lipid Nanoparticles. Proc. 1st. World
Meeting APGI/APV,
R.
H. Müller, W. Mehnert. Potential of Solid Lipid Nanoparticles (SLN) for Controlled Drug
Delivery. Proc. 1st World Meeting APGI/APV,
H.
Weyhers, S. Ehlers, W. Mehnert, H. Hahn, R. H. Müller. Solid Lipid Nanoparticles - Determination of In Vivo
Toxicity. Proc. 1st World Meeting APGI/APV,
K.-H.
Frömming, M. Bergmann, W. Mehnert. Dependence of Quality of Freeze-dried Diazepam
Mannitol on some Manufacturing Conditions. Proc. 1st World Meeting APGI/APV,
C.
Olbrich, W. Mehnert, R.H. Müller. Effect of surfactant and lipid composition on the in
vitro degradation time of solid lipid
nanoparticles (SLN). Proceed. Int. Symp. Control. Rel. Bioact. Mater.
24, 921 (1997).
R.H.
Müller, W. Mehnert, A. Dingler, S.A. Runge, A. zur Mühlen, C. Freitas. Solid lipid nanoparticles (SLNTM,
LipopearlsTM) - present state of
development. Proceed. Int. Symp. Control. Rel. Bioact. Mater.
24, 923 (1997).
Olbrich, C., Mehnert, W., R. H. Müller.In vitro
degradation properties of solid lipid nanoparticles (SLNÒ). Proceed. 2nd World Meeting APGI/APV,
25/28 May 1998, 577-578.
Olbrich,
C., Mehnert, W., R. H. Müller. Development
of an in vitro degradation assay for solid lipid nanoparticles (SLNÒ).
Proceed. 2nd World Meeting APGI/APV, 25/28 May 1998,
627-628.
Maia,
C., A. Gyler, W. Mehnert, R. H. Müller, M. Schäer-Korting. Local tolerability of Solid lipid Nanoparticles
for dermal use. Int. Symp. Control. Rel. Bioact. Mater. 26:
403-404 (1999).
Olbrich, C.,
Liedtke,
S., Jores, K., Mehnert, W., and K. Mäder. Possibilities of non-invasive physicochemical characterisation of
colloidal drug carriers. Proceed Intern Symp Control Rel Bioact Mater 27:
1088-1089 (2000).
Jores,
K., Liedtke, S., Mehnert, W., and K. Mäder. Characterization of solid lipid nanoparticles (SLN™) – how to optimize
the quantity of surfactants. Proceed Intern
Symp Control Rel Bioact Mater
27: 1092-1093 (2000).
Jores, K.,
Mehnert, W., Bunjes, H., Drechsler, M. and K. Mäder. From solid lipid nanoparticles (SLN) to nanospoons.
Visions and reality of colloidal lipid dispersions. Proceed Intern Symp Control Rel Bioact Mater 30: 181 (2003).
Abstracts
Ch.
Kraus, W. Mehnert, K.-H. Frömming. Lösungsvermittlung durch mischmizellare
Systeme und deren Charakterisierung. Arch. Pharm. 320, 978
(1987).
V. Bothmann, W. Mehnert, K.-H. Frömming. Laboratory
scale production of polymer matrix pellets. Acta Pharm. Technol. 34,
17 S (1988).
J.
Norwig, M. Thoss, W. Mehnert, K.-H. Frömming. Röntgendiffraktometrische
Untersuchungen an -Cyclodextrin-Einschlußverbindungen.
Arch. Pharm. 322, 765 (1989).
K.-H.
Frömming, J. Norwig, W. Mehnert. Bildung von
Menadion-Cyclodextrin-Einschlußverbin-
dungen
unter Verwendung von Cyclodextrin-Gemischen. Acta Pharm. Technol. 36, 40 S (1990).
W.G.
Schmidt, W. Mehnert, K.-H. Frömming. Steuerung der Arzneistofffreisetzung aus
Matrixpellets. Arch. Pharm. 323, 770 (1990).
W.G. Schmidt, W. Mehnert, K.-H. Frömming. Spherical
Matrices with Apparent Zero-Order Release. Proceed. Intern. Symp. Control.
Rel. Bioact. Mater. 18,
161 (1991).
A.
Preiss, W. Mehnert, K.-H. Frömming. Die Beeinflussung der
Hydrocortison-Liberation aus Dermatika durch Cyclodextrine. Eur. J. Pharm. Biopharm.
38, 48 S (1992).
H.
Haubitz, W. Mehnert, K.-H. Frömming. Aufbau eines prozeßgesteuerten
Labor-Rotor-Wirbelschichtgranulators zur Herstellung von Retard-Pellets. Eur. J. Pharm. Biopharm.
38, 49 S (1992).
J.
E. Diederichs, W. Mehnert, J. S. Lucks, R. H. Müller. DSC Investigations of Parenteral Fat Emulsions. Eur. J. Pharm. Biopharm. 38,
32 S (1992).
R.
Schuhmann, W. Mehnert, R. H. Müller. Coaleszence Kinetics of Fat Emulsions determined by
Coulter Counter Measurements. Eur. J. Pharm. Biopharm. 38, 43 S (1992).
M. Eder, W. Mehnert, K.-H. Frömming..Influence of
Natural Concomitant Compounds on Dissolving Properties of Digoxin. Eur. J. Pharm. Biopharm. 40, 5 S
(1994).
H. Weyhers, W. Mehnert, R. H. Müller. Production and
Charakterization of Surface-modified "Solid Lipid Nanoparticles"
(SLN). Eur. J. Pharm. Biopharm. 40, 15 S
(1994).
C. Schwarz, W. Mehnert, R. H. Müller. Influence of
Production Parameters of Solid Lipid Nanoparticles (SLN) on the Suitability for
Intravenous Injection. Eur. J. Pharm. Biopharm. 40, 24 S (1994).
C. Freitas, W. Mehnert, R. H. Müller. Stabilization of
"Solid Lipid Nanoparticles" (SLN) by Spray Drying. Eur. J. Pharm. Biopharm. 40, 29 S
(1994).
S. Maaßen, H. Weyhers, W. Mehnert, R. H. Müller.
Surface-Modified Solid Lipid Nanoparticles (SLN) - In Vitro Affinity to Human
Granulocytes. Eur. J.
Pharm. Biopharm. 40, 41 S
(1994).
C. Schwarz, W. Mehnert, R. H. Müller. Influence of
Drug Incorporation and Lyophilisation on the Physical Stability of Solid Lipid
Nanoparticles (SLN). Eur. J. Pharm. Biopharm.
40, 52 S (1994).
A.
zur Mühlen, J.S. Lucks, W. Mehnert, R. H. Müller. Longterm Stability of "Solid Lipid
Nanoparticles" (SLN) for Parenteral Application. Eur. J. Pharm. Biopharm.
40, 53 S (1994).
D.
Rühl, S. Maaßen, C. Schwarz, W. Mehnert, R. H. Müller. Comparative Cytotoxicity of Solid Lipid Nanoparticles
(SLN), Polyester and Cyanoacrylate Particles. Eur. J. Pharm. Biopharm.
40, 61 S (1994).
A.
zur Mühlen, C. Schwarz, W. Mehnert, R. H. Müller. Produktion von "solid
lipid nanoparticles" (SLN) für die kontrollierte Arzneistoffapplikation. Arch.
Pharm. 326, 752 (1993).
A.
Preiss, W. Mehnert, K.-H. Frömming. Die Beeinflussung der
Hydrocortison-Penetration in excidierte
Humanhaut durch Cyclodextrine. Arch. Pharm. 326, 745 (1993).
M.
Sieve, W. Mehnert, K.-H. Frömming. Die Abhängigkeit der Lyophilisatqualität von
einigen Verfahrensparametern unter besonderer Berücksichtigung des
Restlösungsmittelgehalts. Arch. Pharm. 326, 735 (1993).
C.
Schwarz, W. Mehnert, R. H. Müller. Lyophilization of Solid Lipid Nanoparticles (SLN).
Eur. J. of Pharmaceutical Sciences 2, 177
(1994).
A.
zur Mühlen, E. zur Mühlen, H. Niehus, W. Mehnert. Characterisation of Solid Lipid Nanoparticles by
Atomic Force Microscopy. Eur. J. of Pharmaceutical Sciences 2, 178 (1994)
J. Dechandt, W. Mehnert, K.-H. Frömming.Influence of
Hydroxypropyl--Cyclodextrin on the Antimicrobial. Eur. J. of
Pharmaceutical Sciences 2, 179
(1994).
A.
zur Mühlen, W. Mehnert. Freisetzung von Prednisolon aus „Solid Lipid
Nanoparticles“ (SLN).
Abstract-Band,
S. 54, Jahrestagung der DPhG, Jena, 20.-24.9.1995.
H.
Weyhers, M. Lück, W. Mehnert, R. H. Müller. Feste Lipid Nanopartikel -
Inkorporierung von hydrophilen Arzneistoffen. Abstract-Band, S. 161,
Jahrestagung der DPhG, Jena, 20.-24.9.1995.
A.
zur Mühlen, E. zur Mühlen, H. Niehus, W. Mehnert. Atomic Force Microscopy Investigations of Solid Lipid
Nanoparticles. Eur. J. Pharm. Biopharm. 42 (Suppl.), 40 S (1996).
S. Runge, A. zur Mühlen,
H.
Weyhers, W. Mehnert, J. Kreuter, R. H. Müller.
Radiolabelling
of Solid Lipid Nanoparticles (SLN). Eur. J. Pharm. Biopharm. 42
(Suppl.), 42 S (1996).
S. Runge, W. Mehnert, R. H. Müller. SLN (Solid Lipid Nanoparticles), a Novel Formulation
for the Oral Administration of Drugs. Eur. J. of Pharmaceutical Sciences
4 (Suppl.), S132 (1996).
R.
H. Müller, C. Freitas, A. zur Mühlen, W. Mehnert. Long Term stability Investigations of Solid Lipid
Nanoparticles (SLN). Eur. J. of Pharmaceutical Sciences 4 (Suppl.), S132 (1996).
R.
H. Müller, C. Freitas, A. zur Mühlen, W. Mehnert. Solid lipid nanoparticles (SLN) for controlled drug
delivery. Eur. J. of Pharmaceutical Sciences 4 (Suppl.), S75 (1996).
Liedtke, S., Mehnert, W., Mügge, C., and K. Mäder. Resonance spectroscopic methods for the characterisation of colloidal drug carriers. Arch Pharm Pharm Med Chem 333, Suppl. 2: 20 (2000).
Jores, K., Liedtke, S., Mäder, C., and W. Mehnert. Characterization of tensides in colloidal drug carrier systems. Arch Pharm Pharm Med Chem 333, Suppl. 2: 21 (2000)
Liedtke, S.,
Mehnert, W., and K. Mäder. Dependence of
drug incorporation in lipid carrier systems on the drugs structure – an
ESR study. Arch Pharm Pharm Med Chem 334, Suppl. 2:
24 (2001).
Jores, K.,
Mehnert, W., and K. Mäder. Incorporation of drug model substances in colloidal lipid carrier
systems. Arch Pharm Pharm Med Chem 334, Suppl. 2:
77 (2001).
Jores, K.,
Mehnert, W., and K. Mäder. Non-invasive determination of the fate of colloidal lipid
nanodispersions on human skin. Arch Pharm Pharm Med Chem 335,
Suppl. 1: 113 (2002).
Mäder, K.,
Jores, K., Mehnert, W., and T. Plauschin. Non-invasive characterization of drug release
processes by Low Frequency (1.2 GHZ) EPR-Imaging. Arch Pharm Pharm Med Chem 335,
Suppl. 1: 115 (2002).
Mehnert, W.,
Jores, K., and K. Mäder. Lipid nanoparticles as possible drug carriers: a physicochemical
characterization by spectrofluorometric studies. Arch Pharm Pharm Med Chem 335,
Suppl. 1: 117 (2002).
Wissing, S.
A., Mehnert, W., and R. H. Müller. SLN for topical products: In vitro model and in vivo
effects. Arch Pharm Pharm Med Chem 335, Suppl. 1:
124 (2002).
Münster, U.,
Nakamura, C., Jores, K., Mehnert, W., Rummel, S., Schaller, M., Korting, H. C.,
and M. Schäfer-Korting. RU 58841-myristate – a new prodrug with promising properties for acne
and androgenetic alopecia. Arch Pharm Pharm Med Chem 335, Suppl. 1:
131 (2002).
Nakamura, C.,
Mehnert, W., Sivaramakrishnan, R., Kramer, K.D., Korting, H.C.,
Schäfer-Korting, M. Solid lipid nanoparticles as drug carriers for topical
glucocorticoids. DPhG-Jahrestagung 2003
(8.-11.10.2003,
Würzburg), Abstrakt-Band, S. 104.
Nakamura, C.,
Mehnert, W., Sivaramakrishnan, R., Kramer, K.D., Korting, H.C.,
Schäfer-Korting, M. Solid Lipid Nanoparticles for Glucocorticoid Targeting to
Human Skin. Naunyn-Schmiedeberg`s
Archives of Pharmacology 369, Supplement 1: R 7 (2004).
Nakamura, C., Braem, C., Sivaramakrishnan, R., Kramer,
K.D., Schäfer-Korting, M., Mehnert, W. Solid Lipid Nanoparticles for
Glucocorticoide Treatment of Skin Diseases. DPhG.
Landesgruppe Berlin-Brandenburg, “Der wissenschaftliche Nachwuchs stellt sich
vor” (5.7.2004, Berlin), Abstrakt-Band: P 17.
Stecova,
J., Sivaramakrishnan, R., Mehnert, W., Kramer, K.D., Zouboulis, C.C.,
Schäfer-Korting, M. Innovative drug carriers for topical Cyproterone acetate
therapy of androgenetic alopecia and acne, Jahrestagung der Deutschen
Pharmazeutischen Gesellschaft, 6.10.-9.10.2004, Regensburg, Abstract-Band S.148
(P P25).
Stecova, J., Schlupp, P., Mehnert, W., Kramer, K.D.,
Zouboulis, C.C., Schäfer-Korting, M. Nanostructered carriers for topical
cyproterone acetate application to intact and stripped human skin, 9.
Jahrestagung der Gesellschaft für Dermopharmazie, Wien, 14.-15. März 2005.
Braem, C., Herrmann, W., Mehnert, W., Blaschke, T.,
Kramer, K.D., Schäfer-Korting, M. Interaction of different lipid
nanodispersions with spinlabelled cholestane. Jahrestagung
der Deutschen Pharmazeutischen Gesellschaft, 4.-7. Oktober 2006, Marburg,
Abstrakt-Band S. 133 (T015).